BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
- Conditions
- Solid TumorBreast Cancer
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 29
- Registration Number
- NCT00803556
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00803374
- Locations
- 🇺🇸
Local Institution, New York, New York, United States
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 111
- Registration Number
- NCT00798252
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 72
- Registration Number
- NCT00796991
- Locations
- 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
🇺🇸Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT00793897
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: BMS-817378
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00792558
- Locations
- 🇸🇬
Local Institution, Singapore, Singapore
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00788333
- Locations
- 🇬🇧
Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT00780000
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00779428
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 371
- Registration Number
- NCT00778622
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China